- The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks.
- The P-IIIb EXPEDITION-8 study resulted in @8wks. 97.9% GT1, 2, 4, 5 & 6 patients achieved a sustained virologic response 12wks. (SVR12); no case of virologic failures and discontinued treatment were observed
- Maviret is a combination of NS3/4A protease & NS5A inhibitor and is an 8-week, pan-genotypic option (GT1-6) for patients who are new to treatment and without cirrhosis and for GT1, 2, 4, 5 and 6 patients who are new to treatment with compensated cirrhosis
Click here to read full press release/ article | Ref: AbbVie | Image: Independent